Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T21:45:46.515Z.
Calculation as of: 2026-10-06T21:45:46.515Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: c4088ee3877f0fa8fb1d478ebd945bbdf3f6f56484e99899685bc9bfb173ee48
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Aptevo Therapeutics Inc.
Market Cap
$3.93M
EV/EBITDA Ratio
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO |
|---|---|---|
| Aptevo Therapeutics Inc. (APVO) | $3.93M | N/A |
| 60 Degrees Pharmaceuticals, Inc. (SXTP)vs › | $3.90M | N/A |
| GRI Bio, Inc. (GRI)vs › | $4.15M | N/A |
| Evogene Ltd. (EVGN)vs › | $3.65M | N/A |
| Ernexa Therapeutics Inc. (ERNA)vs › | $3.65M | N/A |
| Processa Pharmaceuticals, Inc. (PCSA)vs › | $4.21M | N/A |
| WORK Medical Technology Group Ltd. Class A (WOK)vs › | $3.63M | N/A |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.32M | N/A |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs › | $3.53M | N/A |
| Moolec Science S.A. (MLEC)vs › | $3.50M | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
